董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jurgen Hambrecht | 男 | Non-Executive Director | 78 | 7.09万 | 未持股 | 2026-03-26 |
| Rita Johnson Mills | 女 | Non-Executive Director | 67 | 7.00万 | 未持股 | 2026-03-26 |
| Pierre Gianello | 男 | Non-Executive Director | 68 | 17.32万 | 未持股 | 2026-03-26 |
| Olivier Taelman | 男 | Chief Executive Officer and Executive Director | 53 | 未披露 | 未持股 | 2026-03-26 |
| Virginia Kirby | 女 | Non-Executive Director | 69 | 5.77万 | 未持股 | 2026-03-26 |
| Robelga SRL | 男 | Chairman of the Board and Non-Executive Director | 76 | 11.86万 | 未持股 | 2026-03-26 |
| Wildman Ventures LLC | 男 | Non-Executive Director | 68 | 8.11万 | 未持股 | 2026-03-26 |
| Kevin Rakin | 男 | Non-Executive Director | 64 | 7.07万 | 未持股 | 2026-03-26 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John Landry | 男 | Chief Financial Officer | 54 | 未披露 | 未持股 | 2026-03-26 |
| Olivier Taelman | 男 | Chief Executive Officer and Executive Director | 53 | 未披露 | 未持股 | 2026-03-26 |
| Bruno Onkelinx | 男 | Chief Technology Officer | 53 | 未披露 | 未持股 | 2026-03-26 |
| Scott Holstine | 男 | Chief Commercial Officer | 54 | 未披露 | 未持股 | 2026-03-26 |
董事简历
中英对照 | 中文 | 英文- Jurgen Hambrecht
-
Jurgen Hambrecht，从2016年到2017年担任Nyxoah SA非执行董事，并于2020年重新加入Nyxoah SA的董事会。2013年1月起，他担任Neuroderm Ltd.董事会成员。他曾任职BASF（德国公司）近45年，在世界各地担任各种职务，最后担任监事会主席（从2014年到2020年），担任BASF SE的首席执行官、执行董事会主席和首席合规官。 他目前担任Fuchs Petrolub SE和Trumpf GmbH & Co. KG的监事会主席。他还是Daimler AG和Lufthansa AG的监事会成员。他在德国杜宾根大学（University of Tubingen）获得有机化学博士学位。
Jurgen Hambrecht served BASF SE, a German company, in vario responsibilities around the world for almost 45 years, lastly as CEO then Chairman of the Supervisory Board until 2020. He has been member of the Supervisory Boards of Daimler AG, Daimler Truck AG, Fuchs Petrolub SE, Trumpf SE, Bilfinger SE and Lufthansa AG a.o. Dr. Hambrecht is member of the Board of AYA Gold&Silver (TSX: AYA.TO) and of Blaize Holdings Inc (NASDAQ: BZAI). He earned his doctorate in Chemistry from the University of Tuebingen, Germany. - Jurgen Hambrecht，从2016年到2017年担任Nyxoah SA非执行董事，并于2020年重新加入Nyxoah SA的董事会。2013年1月起，他担任Neuroderm Ltd.董事会成员。他曾任职BASF（德国公司）近45年，在世界各地担任各种职务，最后担任监事会主席（从2014年到2020年），担任BASF SE的首席执行官、执行董事会主席和首席合规官。 他目前担任Fuchs Petrolub SE和Trumpf GmbH & Co. KG的监事会主席。他还是Daimler AG和Lufthansa AG的监事会成员。他在德国杜宾根大学（University of Tubingen）获得有机化学博士学位。
- Jurgen Hambrecht served BASF SE, a German company, in vario responsibilities around the world for almost 45 years, lastly as CEO then Chairman of the Supervisory Board until 2020. He has been member of the Supervisory Boards of Daimler AG, Daimler Truck AG, Fuchs Petrolub SE, Trumpf SE, Bilfinger SE and Lufthansa AG a.o. Dr. Hambrecht is member of the Board of AYA Gold&Silver (TSX: AYA.TO) and of Blaize Holdings Inc (NASDAQ: BZAI). He earned his doctorate in Chemistry from the University of Tuebingen, Germany.
- Rita Johnson Mills
-
Rita Johnson Mills，她最近于2014年8月至2017年12月担任联合梦百合社区计划（UnitedTennessee Community Plan）的总裁兼首席执行官，该计划为超过50万名政府赞助的医疗保健消费者提供服务，年收入超过25亿美元，在此之前，自2006年以来担任UnitedHealthcare Community&State的卓越表现和问责制高级副总裁，。Johnson-Mills女士此前还曾担任Medicare和Medicaid服务中心的Medicaid管理式医疗主任，以及印第安纳州管理式医疗服务公司和Buckeye Health Plan公司的首席执行官，这两家公司都是Centene Corporation的全资子公司。Johnson-Mills女士在林肯大学（Lincoln University）获得B.S.学位，并在俄亥俄州立大学（Ohio State University）获得劳工与人力资源管理硕士学位和公共政策与管理硕士学位。
Rita Johnson Mills,She most recently served from August 2014 to December 2017 as President and Chief Executive Officer of UnitedHealthcare Community Plan of Tennessee, a health plan serving more than 500000 government sponsored healthcare consumers with over $2.5 billion of annual revenue, after having previously served as Senior Vice President, Performance Excellence and Accountability for UnitedHealthcare Community & State since 2006. Ms. Johnson-Mills also previously served as the Director of Medicaid Managed Care for the Centers for Medicare and Medicaid Services and as Chief Executive Officer of Managed Health Services Indiana and Buckeye Health Plan, wholly owned subsidiaries of Centene Corporation. Ms. Johnson-Mills earned a B.S. degree from Lincoln University and an M.A. degree in Labor and Human Resource Management and M.P.A. degree in Public Policy and Management from The Ohio State University. - Rita Johnson Mills，她最近于2014年8月至2017年12月担任联合梦百合社区计划（UnitedTennessee Community Plan）的总裁兼首席执行官，该计划为超过50万名政府赞助的医疗保健消费者提供服务，年收入超过25亿美元，在此之前，自2006年以来担任UnitedHealthcare Community&State的卓越表现和问责制高级副总裁，。Johnson-Mills女士此前还曾担任Medicare和Medicaid服务中心的Medicaid管理式医疗主任，以及印第安纳州管理式医疗服务公司和Buckeye Health Plan公司的首席执行官，这两家公司都是Centene Corporation的全资子公司。Johnson-Mills女士在林肯大学（Lincoln University）获得B.S.学位，并在俄亥俄州立大学（Ohio State University）获得劳工与人力资源管理硕士学位和公共政策与管理硕士学位。
- Rita Johnson Mills,She most recently served from August 2014 to December 2017 as President and Chief Executive Officer of UnitedHealthcare Community Plan of Tennessee, a health plan serving more than 500000 government sponsored healthcare consumers with over $2.5 billion of annual revenue, after having previously served as Senior Vice President, Performance Excellence and Accountability for UnitedHealthcare Community & State since 2006. Ms. Johnson-Mills also previously served as the Director of Medicaid Managed Care for the Centers for Medicare and Medicaid Services and as Chief Executive Officer of Managed Health Services Indiana and Buckeye Health Plan, wholly owned subsidiaries of Centene Corporation. Ms. Johnson-Mills earned a B.S. degree from Lincoln University and an M.A. degree in Labor and Human Resource Management and M.P.A. degree in Public Policy and Management from The Ohio State University.
- Pierre Gianello
-
Pierre Gianello自2018年以来一直担任非执行董事，自2010年以来一直担任公司的医疗顾问。Gianello博士是布鲁塞尔天主教鲁汶大学健康科学部门研究的总协调员，也是UCL与布鲁塞尔天主教鲁汶大学其他国际大学交换学生研究和国际关系副校长的顾问。1997年，Gianello博士成为天主教鲁汶大学实验外科和移植实验室的主任，2005年，他获得了正教授的头衔。从2006年到2009年，他担任研究院长，从2009年到2011年担任副校长。贾内洛教授获得了十个科学奖项，包括霍莱特-达普森斯基金会-1986年协会-1989年克劳德·西蒙教授奖-1989年欧洲肝病基金会奖-2001年圣吕克基金会-2012年他在同行评审的科学期刊上发表了200多篇手稿。Gianello博士获得比利时天主教大学医学、外科和产科博士学位，并在David Sachs教授管理的移植生物学研究中心的马萨诸塞州总医院哈佛医学院完成了博士后培训。
Pierre Gianello was the general coordinator of Research of the Health Sciences Sector at the Université Catholique de Louvain, Brsels, or UCL, and from 2016 to 2022, he was the councilor of the vice rector at the UCL. In 1997, Dr. Gianello became head of the Laboratory of Experimental Surgery and Transplantation at Université Catholique de Louvain and in 2005, he obtained the title of full Professor. From 2006 to 2009, he served as Dean of Research and from 2009 to 2011 as Vice Rector. Professor Gianello has received ten scientific awards, including the Horlait Dapsens Foundation (1986), Association "Professor Jean Morelle" Award (1989), "Claude Simon" Award (1989), Euroliver Foundation Prize (2001), Saint Luc "Foundation" (2012). He is the author of more than 250 published mancripts in peer revied scientific jnals. Dr. Gianello was awarded a Doctor in Medicine, Surgery and Obstetrics at the Université Catholique de Louvain (Belgium), worked as a transplant surgeon at Clinic Saint Luc, Brsels and completed his post doc training at the Massachetts General Hospital, Harvard Medical School in the Transplant Biology Research Centre managed by Prof. David Sachs. - Pierre Gianello自2018年以来一直担任非执行董事，自2010年以来一直担任公司的医疗顾问。Gianello博士是布鲁塞尔天主教鲁汶大学健康科学部门研究的总协调员，也是UCL与布鲁塞尔天主教鲁汶大学其他国际大学交换学生研究和国际关系副校长的顾问。1997年，Gianello博士成为天主教鲁汶大学实验外科和移植实验室的主任，2005年，他获得了正教授的头衔。从2006年到2009年，他担任研究院长，从2009年到2011年担任副校长。贾内洛教授获得了十个科学奖项，包括霍莱特-达普森斯基金会-1986年协会-1989年克劳德·西蒙教授奖-1989年欧洲肝病基金会奖-2001年圣吕克基金会-2012年他在同行评审的科学期刊上发表了200多篇手稿。Gianello博士获得比利时天主教大学医学、外科和产科博士学位，并在David Sachs教授管理的移植生物学研究中心的马萨诸塞州总医院哈佛医学院完成了博士后培训。
- Pierre Gianello was the general coordinator of Research of the Health Sciences Sector at the Université Catholique de Louvain, Brsels, or UCL, and from 2016 to 2022, he was the councilor of the vice rector at the UCL. In 1997, Dr. Gianello became head of the Laboratory of Experimental Surgery and Transplantation at Université Catholique de Louvain and in 2005, he obtained the title of full Professor. From 2006 to 2009, he served as Dean of Research and from 2009 to 2011 as Vice Rector. Professor Gianello has received ten scientific awards, including the Horlait Dapsens Foundation (1986), Association "Professor Jean Morelle" Award (1989), "Claude Simon" Award (1989), Euroliver Foundation Prize (2001), Saint Luc "Foundation" (2012). He is the author of more than 250 published mancripts in peer revied scientific jnals. Dr. Gianello was awarded a Doctor in Medicine, Surgery and Obstetrics at the Université Catholique de Louvain (Belgium), worked as a transplant surgeon at Clinic Saint Luc, Brsels and completed his post doc training at the Massachetts General Hospital, Harvard Medical School in the Transplant Biology Research Centre managed by Prof. David Sachs.
- Olivier Taelman
-
Olivier Taelman自2020年9月起担任执行董事，自2019年11月起担任我们的首席执行官。Taelman先生于2019年7月加入我们公司，担任首席运营和商务官。加入我们公司之前，他曾担任Autonomic Technologies公司（美国医学技术公司）的欧洲副总裁，在那里他曾专注于SPG神经调节的临床、市场准入和商业化，以治疗严重头痛患者，并发展与全球关键意见领袖和管理投资者关系的牢固关系。在加入Autonomic之前，Taelman先生是神经调节公司Nevro的业务总监，在那里他领导了公司欧洲商业结构的发展。在加入Nevro之前，Taelman先生在Medtronic担任了10年的各种职务，领导西欧国家的神经调节部。Taelman先生拥有沃顿大学的执行MBA学位和生物学和物理学学士学位。
Olivier Taelman was Vice President Europe at Autonomic Technologies, Inc., a U.S. medical device company, from December 2015 to June 2019, where he foced on clinical, market access and commercialization of SPG Neuromodulation to treat patients with severe headache and developed strong relationships with global key opinion leaders and managed investor relations. From November 2013 to December 2015, Mr. Taelman was Biness Director, Neuromodulation at Nevro, Corp. (NYSE: NVRO) a neuromodulation company, where he was responsible for commercial operations in Europe and supported the company's transition from clinical stage development to commercial operations. Prior to Nevro, Mr. Taelman held leadership positions at Stryker Corporation and Medtronic plc (NYSE: MDT), within their neurovascular and neuromodulation biness for 10 years. Earlier in his career, Mr. Taelman held commercial roles at Sanofi Aventis (NASDAQ: SNY) and Eli Lilly and Company (NYSE: LLY). Mr. Taelman holds an executive MBA from the Wharton University and a bachelor's degree in Biology and Physics from Hasselt University. - Olivier Taelman自2020年9月起担任执行董事，自2019年11月起担任我们的首席执行官。Taelman先生于2019年7月加入我们公司，担任首席运营和商务官。加入我们公司之前，他曾担任Autonomic Technologies公司（美国医学技术公司）的欧洲副总裁，在那里他曾专注于SPG神经调节的临床、市场准入和商业化，以治疗严重头痛患者，并发展与全球关键意见领袖和管理投资者关系的牢固关系。在加入Autonomic之前，Taelman先生是神经调节公司Nevro的业务总监，在那里他领导了公司欧洲商业结构的发展。在加入Nevro之前，Taelman先生在Medtronic担任了10年的各种职务，领导西欧国家的神经调节部。Taelman先生拥有沃顿大学的执行MBA学位和生物学和物理学学士学位。
- Olivier Taelman was Vice President Europe at Autonomic Technologies, Inc., a U.S. medical device company, from December 2015 to June 2019, where he foced on clinical, market access and commercialization of SPG Neuromodulation to treat patients with severe headache and developed strong relationships with global key opinion leaders and managed investor relations. From November 2013 to December 2015, Mr. Taelman was Biness Director, Neuromodulation at Nevro, Corp. (NYSE: NVRO) a neuromodulation company, where he was responsible for commercial operations in Europe and supported the company's transition from clinical stage development to commercial operations. Prior to Nevro, Mr. Taelman held leadership positions at Stryker Corporation and Medtronic plc (NYSE: MDT), within their neurovascular and neuromodulation biness for 10 years. Earlier in his career, Mr. Taelman held commercial roles at Sanofi Aventis (NASDAQ: SNY) and Eli Lilly and Company (NYSE: LLY). Mr. Taelman holds an executive MBA from the Wharton University and a bachelor's degree in Biology and Physics from Hasselt University.
- Virginia Kirby
-
Virginia 卡比海运目前是xDot Medical，Inc.的全球监管和临床事务副总裁，自2024年6月起担任该职务。卡比海运女士还是Virginia M. 卡比海运咨询公司的顾问，该公司是一家战略咨询公司，提供临床和监管战略及运营方面的咨询服务，自2013年4月起担任该职务。2020年3月至2026年1月，卡比海运女士担任明尼苏达大学技术商业化办公室的常驻主管。在担任这些职务之前，她曾于2016年3月至2017年10月担任Huinno，Inc.的临床和法规事务高级副总裁，2007年至2013年担任Apnex Medical，Inc.的临床和法规事务副总裁，2005年至2006年担任EnteroMedics，Inc.的临床事务和报销副总裁，2003年至2005年担任ev3，Inc.的副总裁。她还曾于1997年至2003年在美敦力公司（NYSE：MDT）担任过多个资历不断增加的职务，并于1983年至1996年在3M公司（NYSE：MMM）担任过多个职务。卡比海运女士目前担任明尼阿波利斯心脏研究所基金会（Minneapolis Heart Institute Foundation）的董事会成员，该基金会是一家非营利性心血管研究和教育基金会，自2021年4月起担任该职务。卡比海运女士获得明尼苏达大学言语与听力科学理学学士学位、普渡大学心理声学/听力学理学硕士学位以及明尼苏达大学卡尔森管理学院/理工学院技术管理理学硕士学位。
Virginia Kirby is currently the Vice President of Global Regulatory and Clinical Affairs at xDot Medical, Inc, serving in this role since June 2024. Ms. Kirby is also a consultant with Virginia M. Kirby Consulting, a strategic consulting company that provides advisory services in clinical and regulatory strategy and operations, and has served in such role since April 2013. From March 2020 to January 2026, Ms. Kirby served as an Executive in Residence for the Office of Technology Commercialization at the University of Minnesota. Prior to these roles, she served as the Senior Vice President of Clinical and Regulatory Affairs for Huinno, Inc. from March 2016 to October 2017, the Vice President of Clinical and Regulatory Affairs at Apnex Medical, Inc. from 2007 to 2013, and the Vice President of Clinical Affairs and Reimbursement at both EnteroMedics, Inc. from 2005 to 2006, and at ev3, Inc. from 2003 to 2005. She also held vario roles of increasing seniority at Medtronic, Inc. (NYSE: MDT) from 1997 to 2003, and at 3M Company (NYSE: MMM) from 1983 to 1996. Ms. Kirby currently serves as a member of the Board of Directors of the Minneapolis Heart Institute Foundation, a non profit cardiovascular research and education foundation, and has served in such role since April 2021. Ms. Kirby received a Bachelor of Science degree in Speech and Hearing Science from the University of Minnesota, a Master of Science degree in Psychoacotics/Audiology from Purdue University and a Master of Science degree in Management of Technology from the University of Minnesota, Carlson School of Management/Institute of Technology. - Virginia 卡比海运目前是xDot Medical，Inc.的全球监管和临床事务副总裁，自2024年6月起担任该职务。卡比海运女士还是Virginia M. 卡比海运咨询公司的顾问，该公司是一家战略咨询公司，提供临床和监管战略及运营方面的咨询服务，自2013年4月起担任该职务。2020年3月至2026年1月，卡比海运女士担任明尼苏达大学技术商业化办公室的常驻主管。在担任这些职务之前，她曾于2016年3月至2017年10月担任Huinno，Inc.的临床和法规事务高级副总裁，2007年至2013年担任Apnex Medical，Inc.的临床和法规事务副总裁，2005年至2006年担任EnteroMedics，Inc.的临床事务和报销副总裁，2003年至2005年担任ev3，Inc.的副总裁。她还曾于1997年至2003年在美敦力公司（NYSE：MDT）担任过多个资历不断增加的职务，并于1983年至1996年在3M公司（NYSE：MMM）担任过多个职务。卡比海运女士目前担任明尼阿波利斯心脏研究所基金会（Minneapolis Heart Institute Foundation）的董事会成员，该基金会是一家非营利性心血管研究和教育基金会，自2021年4月起担任该职务。卡比海运女士获得明尼苏达大学言语与听力科学理学学士学位、普渡大学心理声学/听力学理学硕士学位以及明尼苏达大学卡尔森管理学院/理工学院技术管理理学硕士学位。
- Virginia Kirby is currently the Vice President of Global Regulatory and Clinical Affairs at xDot Medical, Inc, serving in this role since June 2024. Ms. Kirby is also a consultant with Virginia M. Kirby Consulting, a strategic consulting company that provides advisory services in clinical and regulatory strategy and operations, and has served in such role since April 2013. From March 2020 to January 2026, Ms. Kirby served as an Executive in Residence for the Office of Technology Commercialization at the University of Minnesota. Prior to these roles, she served as the Senior Vice President of Clinical and Regulatory Affairs for Huinno, Inc. from March 2016 to October 2017, the Vice President of Clinical and Regulatory Affairs at Apnex Medical, Inc. from 2007 to 2013, and the Vice President of Clinical Affairs and Reimbursement at both EnteroMedics, Inc. from 2005 to 2006, and at ev3, Inc. from 2003 to 2005. She also held vario roles of increasing seniority at Medtronic, Inc. (NYSE: MDT) from 1997 to 2003, and at 3M Company (NYSE: MMM) from 1983 to 1996. Ms. Kirby currently serves as a member of the Board of Directors of the Minneapolis Heart Institute Foundation, a non profit cardiovascular research and education foundation, and has served in such role since April 2021. Ms. Kirby received a Bachelor of Science degree in Speech and Hearing Science from the University of Minnesota, a Master of Science degree in Psychoacotics/Audiology from Purdue University and a Master of Science degree in Management of Technology from the University of Minnesota, Carlson School of Management/Institute of Technology.
- Robelga SRL
-
Robelga SRL是一位企业家，投资于制药和医疗领域。在创立Company之前，他曾于1983年至1995年共同创立并共同管理人类血浆蛋白公司Octapharma AG。他还创立并管理了Omrix Biopharmaceuticals，Inc.，该公司在2008年首次公开发行股票并在纳斯达克上市并被强生收购，他带来了数十年的生命科学经验，指导公司从初创到全球成功。Taub先生拥有INSTEAD（法国枫丹白露）的MBA学位和ANTRP大学的语言学士学位。目前，Taub先生是Aya Gold and Silver（TSX：AYA.TO）以及一家私营太空和国防公司Space Applications Services的董事长。
Robelga SRL is an entrepreneur, investing in the pharmaceutical and medical fields. Prior to founding Company, he co founded and co managed Octapharma AG, a human plasma protein company, from 1983 to 1995. He also founded and managed Omrix Biopharmaceuticals, Inc. through its initial public offering and listing on Nasdaq and its acquisition by Johnson & Johnson in 2008. Mr. Taub holds an MBA from INSTEAD (Fontainebleau, France) and a BA in Languages from the University of Antrp. Currently, Mr. Taub is the Chairman of Aya Gold and Silver (TSX: AYA.TO) and of Space Applications Services, a privately held space and defense company. - Robelga SRL是一位企业家，投资于制药和医疗领域。在创立Company之前，他曾于1983年至1995年共同创立并共同管理人类血浆蛋白公司Octapharma AG。他还创立并管理了Omrix Biopharmaceuticals，Inc.，该公司在2008年首次公开发行股票并在纳斯达克上市并被强生收购，他带来了数十年的生命科学经验，指导公司从初创到全球成功。Taub先生拥有INSTEAD（法国枫丹白露）的MBA学位和ANTRP大学的语言学士学位。目前，Taub先生是Aya Gold and Silver（TSX：AYA.TO）以及一家私营太空和国防公司Space Applications Services的董事长。
- Robelga SRL is an entrepreneur, investing in the pharmaceutical and medical fields. Prior to founding Company, he co founded and co managed Octapharma AG, a human plasma protein company, from 1983 to 1995. He also founded and managed Omrix Biopharmaceuticals, Inc. through its initial public offering and listing on Nasdaq and its acquisition by Johnson & Johnson in 2008. Mr. Taub holds an MBA from INSTEAD (Fontainebleau, France) and a BA in Languages from the University of Antrp. Currently, Mr. Taub is the Chairman of Aya Gold and Silver (TSX: AYA.TO) and of Space Applications Services, a privately held space and defense company.
- Wildman Ventures LLC
-
Wildman Ventures LLC目前是Wildman Ventures，LLC的总裁兼首席执行官，该公司是一家为多家医疗器械和制药公司提供咨询服务的战略咨询公司，自2019年1月以来一直担任这一职务。此外，Wildman先生是Progenerative Medical，Inc.董事会主席，自2022年3月起担任该职务，同时也是PanTher Therapeutics，Inc.的独立董事，自2024年2月起担任该职务。在担任此类职务之前，Wildman先生曾于2000年至2019年1月在强生（NYSE：JNJ）或强生公司担任多个职务，最近在该公司领导了数字手术战略倡议，该倡议制定了机器人手术的综合战略。从1990年到2000年，Wildman先生曾在波士顿科学国际有限公司（纽约证券交易所代码：BSX）担任过各种销售、市场营销、运营和战略规划职务。Wildman先生自2022年11月起担任乌龙制药，有限公司（纳斯达克股票代码：URGN）的董事会成员，previoly于2020年6月至2022年4月担任Precision Healing，Inc.的独立董事。Wildman先生获得圣劳伦斯大学经济学文学学士学位。
Wildman Ventures LLC is currently the President and Chief Executive Officer of Wildman Ventures, LLC, a strategic consulting company that provides advisory services to several medical device and pharmaceutical companies, and has served in such role since January 2019. Additionally, Mr. Wildman is the Chairman of the Board of Progenerative Medical, Inc., where he has served in such role since March 2022, and is also an Independent Director for PanTher Therapeutics, Inc., where he has served in such role since February 2024. Prior to serving in such roles, Mr. Wildman served in vario roles at Johnson & Johnson (NYSE: JNJ), or J&J, from 2000 to January 2019, where he most recently led the Digital Surgery Strategy Initiative that developed an integrated strategy for robotic surgery. From 1990 to 2000, Mr. Wildman served in a variety of sales, marketing, operations and strategic planning roles at Boston Scientific Corporation (NYSE: BSX). Mr. Wildman has served as a member of the Board of Directors of Urogen Pharma, Ltd. (NASDAQ: URGN) since November 2022 and previoly served as an Independent Director of Precision Healing, Inc. from June 2020 to April 2022. Mr. Wildman received a Bachelor of Arts degree in Economics from St. Lawrence University. - Wildman Ventures LLC目前是Wildman Ventures，LLC的总裁兼首席执行官，该公司是一家为多家医疗器械和制药公司提供咨询服务的战略咨询公司，自2019年1月以来一直担任这一职务。此外，Wildman先生是Progenerative Medical，Inc.董事会主席，自2022年3月起担任该职务，同时也是PanTher Therapeutics，Inc.的独立董事，自2024年2月起担任该职务。在担任此类职务之前，Wildman先生曾于2000年至2019年1月在强生（NYSE：JNJ）或强生公司担任多个职务，最近在该公司领导了数字手术战略倡议，该倡议制定了机器人手术的综合战略。从1990年到2000年，Wildman先生曾在波士顿科学国际有限公司（纽约证券交易所代码：BSX）担任过各种销售、市场营销、运营和战略规划职务。Wildman先生自2022年11月起担任乌龙制药，有限公司（纳斯达克股票代码：URGN）的董事会成员，previoly于2020年6月至2022年4月担任Precision Healing，Inc.的独立董事。Wildman先生获得圣劳伦斯大学经济学文学学士学位。
- Wildman Ventures LLC is currently the President and Chief Executive Officer of Wildman Ventures, LLC, a strategic consulting company that provides advisory services to several medical device and pharmaceutical companies, and has served in such role since January 2019. Additionally, Mr. Wildman is the Chairman of the Board of Progenerative Medical, Inc., where he has served in such role since March 2022, and is also an Independent Director for PanTher Therapeutics, Inc., where he has served in such role since February 2024. Prior to serving in such roles, Mr. Wildman served in vario roles at Johnson & Johnson (NYSE: JNJ), or J&J, from 2000 to January 2019, where he most recently led the Digital Surgery Strategy Initiative that developed an integrated strategy for robotic surgery. From 1990 to 2000, Mr. Wildman served in a variety of sales, marketing, operations and strategic planning roles at Boston Scientific Corporation (NYSE: BSX). Mr. Wildman has served as a member of the Board of Directors of Urogen Pharma, Ltd. (NASDAQ: URGN) since November 2022 and previoly served as an Independent Director of Precision Healing, Inc. from June 2020 to April 2022. Mr. Wildman received a Bachelor of Arts degree in Economics from St. Lawrence University.
- Kevin Rakin
-
Kevin Rakin，自2015年11月起担任董事长和董事会成员，自2022年6月起担任执行董事长。他是HighCape Partners （Elutia的投资基金和附属公司）的联合创始人，自2013年以来一直担任HighCape Partners的普通合伙人。此外，Rakin先生从2020年6月至2021年6月担任HighCape Acquisition的首席执行官兼董事会成员，当时HighCape Acquisition与Quantum-Si合并，Rakin先生自2021年起担任董事会成员、提名和治理委员会成员。他也是Nyxoah s.a.（上市医疗器械公司）的董事会成员（2016年以来），在那里他担任其审计和薪酬委员会成员。从2014年到2022年，他担任Oramed Pharmaceuticals Inc.（一家上市制药公司）的董事会成员，在那里他担任其审计和薪酬委员会成员。从2012年到2019年，他还担任Histogenics Corp.（一家上市的生物制药公司）的董事会成员，他在该公司的审计和薪酬委员会任职。他持有Columbia大学工商管理硕士学位，以及南非Cape Town大学学士学位和荣誉学士学位。
Kevin Rakin has been a co founder and partner of HighCape Capital. He served as the President of Shire Regenerative Medicine, Inc. from June 2011 to November 2012. Mr. Rakin was the chairman and chief executive officer of Advanced BioHealing from 2007 until its acquisition by Shire in 2011. Before that, he served as an Executive in Residence at Canaan Partners, a venture capital firm. Until its merger with Clinical Data in 2005, Mr. Rakin was the co founder, President and Chief Executive Officer of Genaissance Pharmaceuticals, Inc., a pharmacogenomics company. He is currently on the boards of a number of private companies as ll as Elutia, Inc. (NASDAQ: ELUT), where he serves as the chairman of the board and Quantum Si (NASDAQ: QSI). Mr. Rakin received an MBA from Columbia University and a B.Com. (Hons) from the University of Cape Town, South Africa. - Kevin Rakin，自2015年11月起担任董事长和董事会成员，自2022年6月起担任执行董事长。他是HighCape Partners （Elutia的投资基金和附属公司）的联合创始人，自2013年以来一直担任HighCape Partners的普通合伙人。此外，Rakin先生从2020年6月至2021年6月担任HighCape Acquisition的首席执行官兼董事会成员，当时HighCape Acquisition与Quantum-Si合并，Rakin先生自2021年起担任董事会成员、提名和治理委员会成员。他也是Nyxoah s.a.（上市医疗器械公司）的董事会成员（2016年以来），在那里他担任其审计和薪酬委员会成员。从2014年到2022年，他担任Oramed Pharmaceuticals Inc.（一家上市制药公司）的董事会成员，在那里他担任其审计和薪酬委员会成员。从2012年到2019年，他还担任Histogenics Corp.（一家上市的生物制药公司）的董事会成员，他在该公司的审计和薪酬委员会任职。他持有Columbia大学工商管理硕士学位，以及南非Cape Town大学学士学位和荣誉学士学位。
- Kevin Rakin has been a co founder and partner of HighCape Capital. He served as the President of Shire Regenerative Medicine, Inc. from June 2011 to November 2012. Mr. Rakin was the chairman and chief executive officer of Advanced BioHealing from 2007 until its acquisition by Shire in 2011. Before that, he served as an Executive in Residence at Canaan Partners, a venture capital firm. Until its merger with Clinical Data in 2005, Mr. Rakin was the co founder, President and Chief Executive Officer of Genaissance Pharmaceuticals, Inc., a pharmacogenomics company. He is currently on the boards of a number of private companies as ll as Elutia, Inc. (NASDAQ: ELUT), where he serves as the chairman of the board and Quantum Si (NASDAQ: QSI). Mr. Rakin received an MBA from Columbia University and a B.Com. (Hons) from the University of Cape Town, South Africa.
高管简历
中英对照 | 中文 | 英文- John Landry
John Landry自2012年8月起担任Vice President兼首席财务官、秘书和财务主管。加入Vapotherm公司之前，他曾担任Salient公司的多种领导职务（从2004年到2011年），包括副总裁会计和总会计师，以及副总裁全球业务开发。Landry从2011年到2012年担任Medtronic Advanced Energy国际营销主管，该公司于2011年8月收购Salient。任职Salient公司之前，他曾担任Bottomline Technologies公司（从2000年到2004年）、Hussey Seating Company（从1997年到2000年）、Coopers&Lybrand LLP（从1994年到1997年）的多种财务领导职务。Landry先生以优异成绩毕业于本特利学院（Bentley College），获得会计学学士学位，是一名非活跃注册会计师。
John Landry has served as Vice President and Chief Financial Officer, Secretary and Treasurer since August 2012. Prior to joining Vapotherm, he held a number of leadership roles at Salient from 2004 to 2011 including VP Accounting & Controller and VP Global Business Development. Mr. Landry also served as Director of International Marketing at Medtronic Advanced Energy from 2011 to 2012 which acquired Salient in August 2011. Prior to his time at Salient, he served in various financial leadership roles at Bottomline Technologies from 2000 to 2004 Hussey Seating Company from 1997 to 2000 and Coopers & Lybrand LLP from 1994 to 1997. Mr. Landry graduated summa cum laude from Bentley College with a BS in Accountancy and is a certified public accountant inactive status.- John Landry自2012年8月起担任Vice President兼首席财务官、秘书和财务主管。加入Vapotherm公司之前，他曾担任Salient公司的多种领导职务（从2004年到2011年），包括副总裁会计和总会计师，以及副总裁全球业务开发。Landry从2011年到2012年担任Medtronic Advanced Energy国际营销主管，该公司于2011年8月收购Salient。任职Salient公司之前，他曾担任Bottomline Technologies公司（从2000年到2004年）、Hussey Seating Company（从1997年到2000年）、Coopers&Lybrand LLP（从1994年到1997年）的多种财务领导职务。Landry先生以优异成绩毕业于本特利学院（Bentley College），获得会计学学士学位，是一名非活跃注册会计师。
- John Landry has served as Vice President and Chief Financial Officer, Secretary and Treasurer since August 2012. Prior to joining Vapotherm, he held a number of leadership roles at Salient from 2004 to 2011 including VP Accounting & Controller and VP Global Business Development. Mr. Landry also served as Director of International Marketing at Medtronic Advanced Energy from 2011 to 2012 which acquired Salient in August 2011. Prior to his time at Salient, he served in various financial leadership roles at Bottomline Technologies from 2000 to 2004 Hussey Seating Company from 1997 to 2000 and Coopers & Lybrand LLP from 1994 to 1997. Mr. Landry graduated summa cum laude from Bentley College with a BS in Accountancy and is a certified public accountant inactive status.
- Olivier Taelman
Olivier Taelman自2020年9月起担任执行董事，自2019年11月起担任我们的首席执行官。Taelman先生于2019年7月加入我们公司，担任首席运营和商务官。加入我们公司之前，他曾担任Autonomic Technologies公司（美国医学技术公司）的欧洲副总裁，在那里他曾专注于SPG神经调节的临床、市场准入和商业化，以治疗严重头痛患者，并发展与全球关键意见领袖和管理投资者关系的牢固关系。在加入Autonomic之前，Taelman先生是神经调节公司Nevro的业务总监，在那里他领导了公司欧洲商业结构的发展。在加入Nevro之前，Taelman先生在Medtronic担任了10年的各种职务，领导西欧国家的神经调节部。Taelman先生拥有沃顿大学的执行MBA学位和生物学和物理学学士学位。
Olivier Taelman was Vice President Europe at Autonomic Technologies, Inc., a U.S. medical device company, from December 2015 to June 2019, where he foced on clinical, market access and commercialization of SPG Neuromodulation to treat patients with severe headache and developed strong relationships with global key opinion leaders and managed investor relations. From November 2013 to December 2015, Mr. Taelman was Biness Director, Neuromodulation at Nevro, Corp. (NYSE: NVRO) a neuromodulation company, where he was responsible for commercial operations in Europe and supported the company's transition from clinical stage development to commercial operations. Prior to Nevro, Mr. Taelman held leadership positions at Stryker Corporation and Medtronic plc (NYSE: MDT), within their neurovascular and neuromodulation biness for 10 years. Earlier in his career, Mr. Taelman held commercial roles at Sanofi Aventis (NASDAQ: SNY) and Eli Lilly and Company (NYSE: LLY). Mr. Taelman holds an executive MBA from the Wharton University and a bachelor's degree in Biology and Physics from Hasselt University.- Olivier Taelman自2020年9月起担任执行董事，自2019年11月起担任我们的首席执行官。Taelman先生于2019年7月加入我们公司，担任首席运营和商务官。加入我们公司之前，他曾担任Autonomic Technologies公司（美国医学技术公司）的欧洲副总裁，在那里他曾专注于SPG神经调节的临床、市场准入和商业化，以治疗严重头痛患者，并发展与全球关键意见领袖和管理投资者关系的牢固关系。在加入Autonomic之前，Taelman先生是神经调节公司Nevro的业务总监，在那里他领导了公司欧洲商业结构的发展。在加入Nevro之前，Taelman先生在Medtronic担任了10年的各种职务，领导西欧国家的神经调节部。Taelman先生拥有沃顿大学的执行MBA学位和生物学和物理学学士学位。
- Olivier Taelman was Vice President Europe at Autonomic Technologies, Inc., a U.S. medical device company, from December 2015 to June 2019, where he foced on clinical, market access and commercialization of SPG Neuromodulation to treat patients with severe headache and developed strong relationships with global key opinion leaders and managed investor relations. From November 2013 to December 2015, Mr. Taelman was Biness Director, Neuromodulation at Nevro, Corp. (NYSE: NVRO) a neuromodulation company, where he was responsible for commercial operations in Europe and supported the company's transition from clinical stage development to commercial operations. Prior to Nevro, Mr. Taelman held leadership positions at Stryker Corporation and Medtronic plc (NYSE: MDT), within their neurovascular and neuromodulation biness for 10 years. Earlier in his career, Mr. Taelman held commercial roles at Sanofi Aventis (NASDAQ: SNY) and Eli Lilly and Company (NYSE: LLY). Mr. Taelman holds an executive MBA from the Wharton University and a bachelor's degree in Biology and Physics from Hasselt University.
- Bruno Onkelinx
Bruno Onkelinx于2020年1月至2021年5月期间担任Cochlear的孵化运营总监，负责为初创企业和规模扩大服务的全球孵化运营。在担任Cochlear孵化运营总监之前，Onkelinx先生还曾担任Cochlear Boulder（）的总裁，负责管理该组织的设计和制造，以及Cochlear的Acotic植入物开发和制造负责人，负责Acotic植入物的全球设计和制造活动。Onkelinx先生在比利时鲁汶的KU Leuven获得了两个工学硕士学位和Biness经济学研究生学位。
Bruno Onkelinx served as the Director of Incubation Operations at Cochlear from January 2020 to May 2021 where he was responsible for global incubation operations serving start ups and scale ups. Prior to serving as Director of Incubation Operations at Cochlear, Mr. Onkelinx also served as President of Cochlear Boulder (), where he managed design and manufacturing for the organization, and Head of Acotic Implant Development and Manufacturing at Cochlear, where he was responsible for global design and manufacturing activities for acotic implants. Mr. Onkelinx received two Master's Degrees in Engineering and a postgraduate degree in Biness Economics from KU Leuven in Leuven, Belgium.- Bruno Onkelinx于2020年1月至2021年5月期间担任Cochlear的孵化运营总监，负责为初创企业和规模扩大服务的全球孵化运营。在担任Cochlear孵化运营总监之前，Onkelinx先生还曾担任Cochlear Boulder（）的总裁，负责管理该组织的设计和制造，以及Cochlear的Acotic植入物开发和制造负责人，负责Acotic植入物的全球设计和制造活动。Onkelinx先生在比利时鲁汶的KU Leuven获得了两个工学硕士学位和Biness经济学研究生学位。
- Bruno Onkelinx served as the Director of Incubation Operations at Cochlear from January 2020 to May 2021 where he was responsible for global incubation operations serving start ups and scale ups. Prior to serving as Director of Incubation Operations at Cochlear, Mr. Onkelinx also served as President of Cochlear Boulder (), where he managed design and manufacturing for the organization, and Head of Acotic Implant Development and Manufacturing at Cochlear, where he was responsible for global design and manufacturing activities for acotic implants. Mr. Onkelinx received two Master's Degrees in Engineering and a postgraduate degree in Biness Economics from KU Leuven in Leuven, Belgium.
- Scott Holstine
Scott Holstine于2023年7月至2024年6月期间担任咨询公司IBEX Passage的创始人和执行董事，并继续担任非执行董事，担任非运营职务。从2021年6月到2023年6月，Holstine先生担任泰利福介入公司的总裁兼总经理，该公司是一家主要专注于介入心脏病学的全球性BINES。此外，2019年6月至2021年5月，他担任Amplifon SPA总经理，负责管理专注于耳鼻喉和听力学市场的Elite Hearing Network。Holstine先生在明尼苏达大学、明尼苏达州明尼阿波利斯的卡尔森管理学院获得MBA学位，并在纽约州圣波因特的美国军事学院获得学士学位。
Scott Holstine served as the Founder and Executive Director of Ibex Passage, a consulting firm, from July 2023 to June 2024 where he continues to serve as non executive director in a non operational role. From June 2021 to June 2023, Mr. Holstine served as President and General Manager of Teleflex Interventional, a global biness foced primarily in interventional cardiology. Additionally, from June 2019 to May 2021, he served as General Manager of Amplifon sPa, where he was responsible for managing the Elite Hearing Network that foced on the otolaryngology and audiology market. Mr. Holstine received his MBA from the University of Minnesota, Carlson School of Management in Minneapolis, Minnesota and his BS from the United States Military Academy in st Point, New York.- Scott Holstine于2023年7月至2024年6月期间担任咨询公司IBEX Passage的创始人和执行董事，并继续担任非执行董事，担任非运营职务。从2021年6月到2023年6月，Holstine先生担任泰利福介入公司的总裁兼总经理，该公司是一家主要专注于介入心脏病学的全球性BINES。此外，2019年6月至2021年5月，他担任Amplifon SPA总经理，负责管理专注于耳鼻喉和听力学市场的Elite Hearing Network。Holstine先生在明尼苏达大学、明尼苏达州明尼阿波利斯的卡尔森管理学院获得MBA学位，并在纽约州圣波因特的美国军事学院获得学士学位。
- Scott Holstine served as the Founder and Executive Director of Ibex Passage, a consulting firm, from July 2023 to June 2024 where he continues to serve as non executive director in a non operational role. From June 2021 to June 2023, Mr. Holstine served as President and General Manager of Teleflex Interventional, a global biness foced primarily in interventional cardiology. Additionally, from June 2019 to May 2021, he served as General Manager of Amplifon sPa, where he was responsible for managing the Elite Hearing Network that foced on the otolaryngology and audiology market. Mr. Holstine received his MBA from the University of Minnesota, Carlson School of Management in Minneapolis, Minnesota and his BS from the United States Military Academy in st Point, New York.